b'Advancing the fight against cancer.Cancer cantTake awaymy optimism. In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committedto realizing the promise of precision medicine for cancer. We seek to develop targeted therapies to better serve patients and ensure the right drug getsto the right patient.clovisoncology.comBrava is developing point-of-care tests forThe First Bone Graft Approved for Cervical Fusionmedical settings where lab-quality results are vital in making time-critical decisions. Powered by P-15 Osteogenic Cell Binding PeptideCOVID-19 Cerapedics is an advanced orthobiologics company focused The Brava COVID-19 Antibody Panel is aondeveloping and commercializing its proprietary small peptide quantitative high-performance, 5-minute test. (P-15) technology platform.IDE STUDY: 12 monthsHost-Response Panels i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide These mulitplex panels measure biomarkersas an attachment factor to stimulate the natural bone healing that appear early in acute infections andprocess. This novel mechanism of action is designed to support saferandmorepredictableboneformationcomparedtoOsteogenic assess the cytokine storm associated with badcommercially available bone growth factors. Cell Receptor outcomes of sepsis and COVID-19.IntegrinsVisitwww.cerapedics.com/tour to take a tour and learn Cardiac Markers how i-FACTOR is made. Attachment to P-15 PeptideThe Brava hs-cTnI Test is a NextGen blood testIndication for use: i-FACTOR Peptide Enhanced Bone Graft is indicated for use in skeletally mature patients for reconstruction of a degenerated cervical disc at one level from C3-C4 to C6-C7 following single level discectomy for for heart attack. This high-sensitivity troponinintractable radiculopathy (arm pain and/or a neurological deficit), with or without neck pain, or myelopathy due to a single-level abnormality localized to the disc space, and corresponding to at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence assay will enable faster diagnosis or rule-out/ of osteophytes), and/or visible loss of disc height as compared to adjacent levels, after failure of at least 6 weeks of conservative treatment. i-FACTOR Peptide Enhanced Bone Graft must be used inside an allograft bone ring and with discharge of low-risk patients. Safe dischargesupplemental anterior plate fixation.reduces unnecessary admissions and reducesBrava is a proud supporter of CBSA and costs to the healthcare system. the Colorado life sciences ecosystem.Learn more at www.BravaDx.comBrava CBSA ad3.indd 1 6/25/2020 4:24:29 PM36BIOSCIENCECOLORADO//2020-2021 BIOSCIENCECOLORADO//2020-202137'